Yi-Heng Chen

This inventor holds 18 USPTO granted patents and 5 published patent applications, plus 1 CIPO patent and 13 EPO patents, primarily in Pharmaceutical Inhibitors. Top assignees: Merck Sharp + Dohme Corp., Mochida Pharmaceutical Co., Ltd., Merck + Co., Inc.. Active years: 2010-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yi-Heng Chen. Retrieved from https://idiyas.com/inventor/yi-heng-chen-ni8obx72

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 18 (Patent Applications = 5)

% Patents Active = 88.9

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 13 (Patent Applications = 11)

Average Co-Inventor Count = 9.7

ph-index = 6

Forward Citations = 107(Granted Patents)

Company Filing History:

16 out of 2,405

Merck Sharp + Dohme Corp.

patents

3 out of 229

Mochida Pharmaceutical Co., Ltd.

Merck Sharp & Dohme LLC

patents

5. 1 out of 1

Mochida Paraceuticals Co., Ltd.

patent

where one patent can have more than one assignee

Years Active: 2010-2026

Loading Chart...

Areas of Expertise:

RIPK1 Inhibitors

LRRK2 Inhibitors

CETP Inhibitors

Soluble Guanylate Cyclase

Factor IXa Inhibitors

TrkA Kinase Inhibitors

Pharmaceutical Compositions

Oxazolidinone Derivatives

Cyclic Amine Substitutes

Stimulants

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12643904 - RIPK1 inhibitors and methods of use (2026-06-02),

2. 12319671 - 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof (2025-06-03),

3. 10428076 - Soluble guanylate cyclase stimulators (2019-10-01),

4. 10189819 - Factor IXa inhibitors (2019-01-29),

5. 10030027 - Soluble guanylate cyclase stimulators (2018-07-24),

6. 9914727 - Factor IXa inhibitors (2018-03-13),

7. 9862716 - TRKA kinase inhibitors, compositions and methods thereof (2018-01-09),

8. 9815846 - TrkA kinase inhibitors, compositions and methods thereof (2017-11-14),

9. 9708308 - Factor IXa inhibitors (2017-07-18),

10. 9695198 - Factor IXa inhibitors (2017-07-04),

11. 9365574 - Soluble guanylate cyclase activators (2016-06-14),

12. 9221834 - Cyclic amine substituted oxazolidinone CETP inhibitor (2015-12-29),

13. 8440702 - 1,3-oxazolidin -2-one derivatives useful as CETP inhibitors (2013-05-14),

14. 7935727 - CETP inhibitors (2011-05-03),

15. 7915271 - 1,3-oxazolidin-2-one derivatives useful as CETP inhibitors (2011-03-29),

Title: Yi-Heng Chen: Innovator in Pharmaceutical Chemistry

Introduction

Yi-Heng Chen is a prominent inventor based in Whippany, NJ, with a remarkable portfolio of 17 patents. His work primarily focuses on pharmaceutical compositions and their applications in treating various diseases, including Parkinson's Disease.

Latest Patents

Among his latest patents, Yi-Heng Chen has developed 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives as LRRK2 inhibitors. This invention is directed towards certain substituted compounds that act as potent inhibitors of LRRK2 kinase, which may be beneficial in treating or preventing diseases associated with this kinase, particularly Parkinson's Disease. Additionally, he has worked on soluble guanylate cyclase stimulators, which are compounds that can modulate the body's production of cyclic guanosine monophosphate (cGMP). These compounds are suitable for therapy and prophylaxis of diseases linked to disturbed cGMP balance.

Career Highlights

Yi-Heng Chen has made significant contributions to the pharmaceutical industry through his work at notable companies such as Merck Sharp & Dohme Corporation and Mochida Pharmaceutical Co., Ltd. His innovative research has led to advancements in drug development and therapeutic applications.

Collaborations

Throughout his career, Yi-Heng Chen has collaborated with esteemed colleagues, including Cameron James Smith and Zhijian Lu. These partnerships have fostered a collaborative environment that enhances the development of groundbreaking pharmaceutical solutions.

Conclusion

Yi-Heng Chen's contributions to pharmaceutical chemistry and his innovative patents underscore his role as a leading inventor in the field. His work continues to impact the treatment of significant health challenges, particularly in relation to Parkinson's Disease.

Profile summary based on public USPTO records.